Scientific Approach
Pipeline
INBRX-109
INBRX-106
INBRX-105
INBRX-101
Investors
Patients
Partners
Who We Are
Team
Contact Us
News Releases
Month Year
Su
Mo
Tu
We
Th
Fr
Sa
25
26
27
28
29
30
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
3
4
5
Cancel
Go
Month Year
Su
Mo
Tu
We
Th
Fr
Sa
25
26
27
28
29
30
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
3
4
5
Cancel
Go
Year
All Years
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
Keywords
Go
Advanced Search
Search
Search Headlines Only
From
To
Asset Types
Photos
Video
Audio
Documents
Events
Standard
Nov 14, 2024
Inhibrx Biosciences Reports Third Quarter 2024 Financial Results
Nov 4, 2024
Inhibrx Prevails in Trade Secret Case, Reaffirming Its Commitment to Integrity and Innovation
Aug 13, 2024
Inhibrx Biosciences Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
May 24, 2024
Inhibrx Inc. Stockholders Approve Sale of INBRX-101 to Sanofi
May 10, 2024
Inhibrx, Inc. Announces Updated When-Issued Trading Date for Anticipated Spin-Off
May 8, 2024
Inhibrx, Inc. Announces Record Date and Expected Distribution Time for Anticipated Spin-Off and the Expected Merger Effective Time for Anticipated Merger
Feb 28, 2024
Inhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial Results
Jan 23, 2024
Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B
Nov 9, 2023
Inhibrx Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
Nov 2, 2023
Inhibrx Announces Preliminary Data from the Phase 1 Trial of INBRX-109 for the Treatment of Ewing Sarcoma
Oct 18, 2023
Inhibrx Announces Participation in Upcoming Scientific Conferences
Aug 29, 2023
Inhibrx Announces $200 Million Private Placement Financing
Aug 7, 2023
Inhibrx Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
May 8, 2023
Inhibrx Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
Apr 26, 2023
Inhibrx Initiates a Registration-Enabling Trial of INBRX-101 in AATD and Announces Lift of Partial Clinical Hold on INBRX-109 DR5 Agonist Trials
Mar 6, 2023
Inhibrx Reports Fourth Quarter and Fiscal Year 2022 Financial Results
Jan 4, 2023
NorthStar Medical Radioisotopes and Inhibrx Enter into Collaboration Agreement for the Development and Production of Radiopharmaceutical Candidates
Nov 18, 2022
Inhibrx Announces Participation in Upcoming Investor Conference
Nov 16, 2022
Inhibrx Announces Updated Efficacy and Safety Data from the Expansion Cohorts in the Phase 1 Trial of INBRX-109 for the Treatment of Chondrosarcoma
Nov 7, 2022
Inhibrx Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights
Oct 20, 2022
Inhibrx Announces Participation in Upcoming Scientific Conferences
Aug 15, 2022
European Medicines Agency Grants Orphan Drug Designation to INBRX-109 for the Treatment of Chondrosarcoma
Aug 8, 2022
Inhibrx Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights
Jun 30, 2022
Inhibrx Announces Completion of Phase 1 Combination Dose Escalation for INBRX-105, a Novel Targeted 4-1BB Agonist, and Draws an Additional $60 Million from Oxford Finance
May 19, 2022
Inhibrx Announces Details of Presentation at 2022 ASCO Annual Meeting
Show
5
10
25
50
100
per page
«
1
2
3
»
